Fucoidan Assisted Eradication of Helicobacter Pylori

Last updated: December 6, 2023
Sponsor: Nanjing First Hospital, Nanjing Medical University
Overall Status: Active - Recruiting

Phase

1/2

Condition

N/A

Treatment

Amoxicillin combined with vonoprazan and fucoidan

Amoxicillin combined with vonoprazan

Clinical Study ID

NCT05461508
KY20220518-02-KS-01
  • Ages 18-70
  • All Genders

Study Summary

The purpose of this study is to investigate whether the eradication rate of H.pylori will be improved when adding fucoidan to the duplex scheme combination of amoxicillin and vonoprazan, and to explore the effect of fucoidan on gastrointestinal flora of patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age 18-65 years old;
  2. Patients diagnosed as HP positive;
  3. Patients who have not received HP eradication treatment in the past, or who havefailed in the early eradication but have not received eradication treatment withinhalf a year;
  4. Voluntarily participate in this trial and sign the informed consent form.

Exclusion

Exclusion Criteria:

  1. Allergic to the study drug (penicillin allergy, etc.);
  2. Patients with chronic gastritis and peptic ulcer;
  3. Patients who have received HP eradication treatment within half a year;
  4. Antibiotics and bismuth agents were used 4 weeks before the start of the studytreatment, and histamine H2 receptor antagonists or PPIs were used 2 weeks before thestart of the study treatment;
  5. Use adrenocortical hormones, non steroidal anti-inflammatory drugs or anticoagulants;
  6. History of esophageal or gastric surgery;
  7. Pregnant and lactating women;
  8. Suffering from serious accompanying diseases, such as liver disease, cardiovasculardisease, lung disease, kidney disease;

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Amoxicillin combined with vonoprazan and fucoidan
Phase: 1/2
Study Start date:
October 01, 2022
Estimated Completion Date:
July 31, 2024

Study Description

After being informed about the study and potential risks, all patients giving written informed consent will undergo a 1-week screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirement will be included in this simultaneous blind test. A total of 60 patients with HP infection were enrolled in this study. All patients were randomly divided into two groups according to the ratio of 1:1. Group A was given vonoprazan 20mg bid, amoxicillin 1000mg TID, fucoidan 1000mg bid for 14 consecutive days; Group B was given vonoprazan 20mg bid and amoxicillin 1000mg TID for 14 days. On the 10th and 14th days of treatment, the researchers will follow up the patients' adverse reactions and medication compliance. The feces of the subjects were collected one day before the treatment, and on the 14th and 44th days after the treatment; After 4 weeks of drug withdrawal, all subjects will be reexamined with 13C-UBT.

Connect with a study center

  • Nanjing First Hospital, Nanjing Medical University

    Nanjing, Jiangsu 210000
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.